[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE499442T1 - Modifizierte genomische rna des menschlichen hepatitis-c-virus mit autonomer replikationskompetenz - Google Patents

Modifizierte genomische rna des menschlichen hepatitis-c-virus mit autonomer replikationskompetenz

Info

Publication number
ATE499442T1
ATE499442T1 AT05781421T AT05781421T ATE499442T1 AT E499442 T1 ATE499442 T1 AT E499442T1 AT 05781421 T AT05781421 T AT 05781421T AT 05781421 T AT05781421 T AT 05781421T AT E499442 T1 ATE499442 T1 AT E499442T1
Authority
AT
Austria
Prior art keywords
coding sequence
protein coding
genomic rna
virus genomic
hepatitis
Prior art date
Application number
AT05781421T
Other languages
English (en)
Inventor
Takaji Wakita
Takanobu Eminence-Ishikawabashi Kato
Tomoko Date
Michiko Miyamoto
Ralf Bartenschlager
Jun-Ichi Tanabe
Saburo Sone
Original Assignee
Tokyo Metropolitan Org Med Res
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokyo Metropolitan Org Med Res, Toray Industries filed Critical Tokyo Metropolitan Org Med Res
Application granted granted Critical
Publication of ATE499442T1 publication Critical patent/ATE499442T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT05781421T 2004-08-24 2005-08-24 Modifizierte genomische rna des menschlichen hepatitis-c-virus mit autonomer replikationskompetenz ATE499442T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2004243975 2004-08-24
JP2004290801 2004-10-01
JP2005069725 2005-03-11
JP2005069527 2005-03-11
PCT/JP2005/015833 WO2006022422A1 (ja) 2004-08-24 2005-08-24 自律複製能を有する改変されたヒトｃ型肝炎ウイルスゲノムrna

Publications (1)

Publication Number Publication Date
ATE499442T1 true ATE499442T1 (de) 2011-03-15

Family

ID=35967617

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05781421T ATE499442T1 (de) 2004-08-24 2005-08-24 Modifizierte genomische rna des menschlichen hepatitis-c-virus mit autonomer replikationskompetenz

Country Status (13)

Country Link
US (2) US8454973B2 (de)
EP (1) EP1801209B1 (de)
JP (1) JP4931591B2 (de)
KR (1) KR101262773B1 (de)
CN (1) CN101048502B (de)
AT (1) ATE499442T1 (de)
AU (1) AU2005275713B2 (de)
CA (1) CA2578021C (de)
DE (1) DE602005026545D1 (de)
HK (1) HK1112481A1 (de)
PL (1) PL1801209T3 (de)
PT (1) PT1801209E (de)
WO (1) WO2006022422A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1794183A2 (de) * 2004-10-01 2007-06-13 Novartis Vaccines and Diagnostics S.r.l. Replikationssystem für hepatitis c virus
WO2006096459A2 (en) 2005-03-04 2006-09-14 The Rockefeller University Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
US8364417B2 (en) * 2007-02-15 2013-01-29 454 Life Sciences Corporation System and method to correct out of phase errors in DNA sequencing data by use of a recursive algorithm
ES2626620T3 (es) 2006-02-16 2017-07-25 454 Life Sciences Corporation Sistema y método para corregir errores de extensión de cebadores en datos de secuencias de ácidos nucleicos
JP2008161080A (ja) * 2006-12-27 2008-07-17 Japan Health Science Foundation Ｃ型肝炎ウイルス阻害剤を検出するためのアッセイ方法
US8945584B2 (en) 2007-04-13 2015-02-03 Hvidovre Hospital Cell culture system of a hepatitis C genotype 3a and 2a chimera
US8454974B2 (en) 2007-04-13 2013-06-04 Hvidovre Hospital Adaptive mutations allow establishment of JFH1-based cell culture systems for hepatitis C virus genotype 4A
EP2711427A1 (de) * 2007-04-27 2014-03-26 Advanced Life Science Institute, Inc. HCV-Gen
WO2008141651A1 (en) 2007-05-18 2008-11-27 Hvidovre Hospital Efficient cell culture system for hepatitis c virus genotype 5a
EP2186893A4 (de) * 2007-07-13 2010-10-20 Jp Nat Inst Infectious Disease Herstellung und verwendung eines mit einem epitop-tag versehenen hepatitis-c-viruspartikels
US20100291545A1 (en) 2007-07-25 2010-11-18 Takaji Wakita Antibody having inhibitory activity on infection with hepatitis c virus (hcv) and use thereof
US8563706B2 (en) 2007-12-20 2013-10-22 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 1A and 1B
US8569472B2 (en) 2007-12-20 2013-10-29 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 6A
WO2009131203A1 (ja) 2008-04-25 2009-10-29 東レ株式会社 C型肝炎ウイルス由来のキメラ遺伝子を含む核酸
US8663653B2 (en) 2008-08-15 2014-03-04 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 2B
US8506969B2 (en) 2008-08-15 2013-08-13 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 7a
CA2738982C (en) 2008-09-30 2016-05-24 Toray Industries, Inc. Antibody binding to envelope protein 2 of hepatitis c virus and method for identifying genotype of hepatitis c virus using the same
US8772022B2 (en) 2008-10-03 2014-07-08 Hvidovre Hospital Hepatitis C virus expressing reporter tagged NS5A protein
JP5692738B2 (ja) * 2009-07-28 2015-04-01 国立大学法人 鹿児島大学 ウイルスの濃縮方法および磁性体組成物
US20120251572A1 (en) 2009-09-30 2012-10-04 Takaji Wakita Hepatitis c virus vaccine composition
EP2495256A4 (de) 2009-10-30 2013-09-25 Toray Industries Antikörper mit hemmender wirkung auf infektionen mit hepatitis-c-virus (hcv) und seine verwendung
EP3290529B1 (de) 2010-06-11 2019-05-22 Life Technologies Corporation Alternative nukleotidflüsse in verfahren zur sequenzierung durch synthese
CN103261411B (zh) * 2010-10-08 2015-01-28 株式会社先端生命科学研究所 丙型肝炎病毒基因
US10273540B2 (en) 2010-10-27 2019-04-30 Life Technologies Corporation Methods and apparatuses for estimating parameters in a predictive model for use in sequencing-by-synthesis
EP2633470B1 (de) 2010-10-27 2016-10-26 Life Technologies Corporation Prädiktives modell zur verwendung für sequenzierung nach synthese
WO2012118555A1 (en) 2010-12-29 2012-09-07 Life Technologies Corporation Time-warped background signal for sequencing-by-synthesis operations
US20130060482A1 (en) 2010-12-30 2013-03-07 Life Technologies Corporation Methods, systems, and computer readable media for making base calls in nucleic acid sequencing
EP3582224A1 (de) 2010-12-30 2019-12-18 Life Technologies Corporation Modelle zur analyse von daten aus sequenzierung-mit-synthese-operationen
US10241075B2 (en) 2010-12-30 2019-03-26 Life Technologies Corporation Methods, systems, and computer readable media for nucleic acid sequencing
EP2692861A4 (de) 2011-03-31 2014-12-17 Jp Nat Inst Infectious Disease Nukleinsäurekonstrukt mit aus dem von genotyp-1b-hcv-genom abgeleiteter nukleinsäure, damit transfektierte hcv-genom-replizierende zellen und verfahren zur herstellung infektiöser hcv-partikel
CN103764845B (zh) 2011-04-08 2016-02-17 生命科技股份有限公司 用于合成测序中的相保护试剂流排序
CA2837279A1 (en) 2011-05-31 2012-12-06 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Mutant replicon derived from genome of hepatitis c virus j6cf strain
AU2012302666B2 (en) 2011-08-31 2017-05-25 Inserm Institut National De La Sante Et De La Recherche Medicale Nucleic acid construct including nucleic acid derived from genotype 3a HCV genome
US10704164B2 (en) 2011-08-31 2020-07-07 Life Technologies Corporation Methods, systems, computer readable media, and kits for sample identification
EP2802597A1 (de) * 2012-01-13 2014-11-19 Gilead Pharmasset LLC Kristallstruktur von hcv-polymerasekomplexen und anwendungsverfahren
US9646132B2 (en) 2012-05-11 2017-05-09 Life Technologies Corporation Models for analyzing data from sequencing-by-synthesis operations
US10329608B2 (en) 2012-10-10 2019-06-25 Life Technologies Corporation Methods, systems, and computer readable media for repeat sequencing
US20140296080A1 (en) 2013-03-14 2014-10-02 Life Technologies Corporation Methods, Systems, and Computer Readable Media for Evaluating Variant Likelihood
US9926597B2 (en) 2013-07-26 2018-03-27 Life Technologies Corporation Control nucleic acid sequences for use in sequencing-by-synthesis and methods for designing the same
EP3053072B1 (de) 2013-10-04 2024-02-21 Life Technologies Corporation Verfahren und systeme zur modellierung von phaseneffekten in der sequenzierung mittels terminierungschemie
WO2016060974A1 (en) 2014-10-13 2016-04-21 Life Technologies Corporation Methods, systems, and computer-readable media for accelerated base calling
EP3295345B1 (de) 2015-05-14 2023-01-25 Life Technologies Corporation Barcodesequenzen sowie zugehörige systeme und verfahren
US10619205B2 (en) 2016-05-06 2020-04-14 Life Technologies Corporation Combinatorial barcode sequences, and related systems and methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4021493B2 (ja) * 1996-11-08 2007-12-12 ザ ガヴァメント オブ ザ ユナイテッド ステイツ オブ アメリカ、レプリゼンテッド バイ ザ セクレタリー、 デパートメント オブ ヘルス アンド ヒューマン サーヴィスィズ Ｃ型肝炎ウイルス様粒子の合成および精製
EP1185664B1 (de) * 1999-06-04 2007-05-16 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES Klonierte genome von infektiösen hepatitis c viren genotyp 2a und deren verwendungen
ATE413190T1 (de) * 1999-12-01 2008-11-15 Novartis Vaccines & Diagnostic Hervorrufen von antikörpern spezifisch für hepatitis c virus (hcv)
IL137522A (en) * 2000-07-26 2007-06-17 Drk Blutspendediendst Baden Wu HCV human monoclonal antibody E2 glycoprotein antibody
JP4880116B2 (ja) * 2000-12-01 2012-02-22 財団法人 東京都医学総合研究所 劇症ｃ型肝炎ウイルス株の遺伝子
EP1490389A4 (de) 2002-04-03 2006-08-09 Smithkline Beecham Corp Subgenomische replicons des hepatitis-c-virus
US7935676B2 (en) * 2003-05-26 2011-05-03 Toray Industries Inc. Nucleic acid construct containing a nucleic acid derived from the genome of hepatitis C virus (HCV) of genotype 2A, and a cell having such nucleic acid construct introduced therein
EP1794183A2 (de) * 2004-10-01 2007-06-13 Novartis Vaccines and Diagnostics S.r.l. Replikationssystem für hepatitis c virus
WO2006096459A2 (en) 2005-03-04 2006-09-14 The Rockefeller University Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
WO2009131203A1 (ja) * 2008-04-25 2009-10-29 東レ株式会社 C型肝炎ウイルス由来のキメラ遺伝子を含む核酸

Also Published As

Publication number Publication date
US20090176200A1 (en) 2009-07-09
DE602005026545D1 (de) 2011-04-07
EP1801209A4 (de) 2007-12-05
JPWO2006022422A1 (ja) 2008-05-08
KR101262773B1 (ko) 2013-05-10
US20130115592A1 (en) 2013-05-09
PL1801209T3 (pl) 2011-07-29
HK1112481A1 (en) 2008-09-05
AU2005275713A1 (en) 2006-03-02
US8454973B2 (en) 2013-06-04
CA2578021A1 (en) 2006-03-02
KR20070045333A (ko) 2007-05-02
AU2005275713B2 (en) 2010-08-05
WO2006022422A1 (ja) 2006-03-02
EP1801209A1 (de) 2007-06-27
US9175269B2 (en) 2015-11-03
JP4931591B2 (ja) 2012-05-16
CA2578021C (en) 2014-11-18
CN101048502B (zh) 2012-03-21
CN101048502A (zh) 2007-10-03
EP1801209B1 (de) 2011-02-23
PT1801209E (pt) 2011-05-26

Similar Documents

Publication Publication Date Title
ATE499442T1 (de) Modifizierte genomische rna des menschlichen hepatitis-c-virus mit autonomer replikationskompetenz
Shayan et al. Crimean-Congo hemorrhagic fever
Jones et al. The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus
Ji et al. Studying classical swine fever virus: making the best of a bad virus
Mandl et al. Spontaneous and engineered deletions in the 3′ noncoding region of tick-borne encephalitis virus: construction of highly attenuated mutants of a flavivirus
Fan et al. The intrinsic disorder status of the human hepatitis C virus proteome
Epstein et al. Identification of GBV-D, a novel GB-like flavivirus from old world frugivorous bats (Pteropus giganteus) in Bangladesh
WO2009014216A1 (ja) Ｃ型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体およびその用途
WO2006096459A3 (en) Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
JP2008516610A5 (de)
DK1629091T3 (da) Præparat indeholdende polyproteinet NS3/NS4 og polypeptidet NS5B af HCV, ekspressionsvektorer omfattende tilsvarende nukleinsyresekvenser og terapeutisk anvendelse deraf
EP1930416A4 (de) Neues rekombinantes partikel mit ähnlichkeit zum menschlichen hepatitis-c-virus und verfahren zur herstellung davon
Li et al. Recovery of a chemically synthesized Japanese encephalitis virus reveals two critical adaptive mutations in NS2B and NS4A
Naderi et al. Hepatitis C virus and vaccine development
Londono-Renteria et al. A brief review of West Nile virus biology
Manickam et al. Modeling HCV disease in animals: virology, immunology and pathogenesis of HCV and GBV-B infections
Khasnatinov et al. Tick-borne encephalitis virus structural proteins are the primary viral determinants of non-viraemic transmission between ticks whereas non-structural proteins affect cytotoxicity
Tellinghuisen et al. The NS5A protein of bovine viral diarrhea virus contains an essential zinc-binding site similar to that of the hepatitis C virus NS5A protein
US20150152392A1 (en) Hcv full-length infectious cell culture systems and applications thereof
ATE555800T1 (de) Zusammensetzung mit dem polyprotein ns3/ns4 und dem polypeptid ns5b von hcv, expressionsvektoren mit den entsprechenden nukleinsäuresequenzen und ihre therapeutische verwendung
Lattwein et al. Pestivirus virion morphogenesis in the absence of uncleaved nonstructural protein 2-3
Varshney et al. A review on an update of NS5B polymerase hepatitis C virus inhibitors
Imhof et al. Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6
Sarwar et al. NS4A protein as a marker of HCV history suggests that different HCV genotypes originally evolved from genotype 1b
WO2005032329A3 (en) Methods and compositions for identifying anti-hcv agents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties